CMS has released the Q2 2020 drug pricing files for both average sales price (ASP) and not otherwise classified (NOC) drugs. These changes are effective April 1, 2020 and will remain in effect until either a correction or the next scheduled update is made by CMS.

The data used for the Q2 2020 reimbursement files is based on the Q4 2019 sales data submitted to CMS by drug manufacturers. We encourage you to review the revised drug payment limit files, including reimbursement allowables on NOC drugs, on the CMS website.

Access the Payment Limit Report